TELESCOPE for Lung Cancer

(TELESCOPE-H Trial)

Overseen By Evelyn Arana, DrPH

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Rutgers, The State University of New Jersey

Disqualifiers: Non-English speakers, Non-Hispanic, Lung cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to adapt a program called TELESCOPE, a new support initiative, to better serve Hispanic individuals at high risk for lung cancer. Researchers seek to evaluate its effectiveness and community acceptance when delivered by bilingual guides. Participants will either receive this new support or continue with their regular care to compare results, focusing on lung cancer screening. Those who identify as Hispanic, are current or former smokers with a significant smoking history, and can attend a non-urgent doctor visit may be suitable candidates. As an unphased trial, this study offers a unique opportunity to contribute to research that could enhance lung cancer screening support for the Hispanic community.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the TELESCOPE intervention is safe for Hispanics at high risk for lung cancer?

Research has shown that the TELESCOPE program helps patients make informed choices about lung cancer screening. In past studies, patients responded well to this type of program. It involves conversations between patients and healthcare providers, focusing on shared decision-making. These discussions aim to ensure patients understand their lung cancer screening options.

No specific reports of negative effects from the TELESCOPE program itself have emerged. The program guides patients using telehealth and patient navigators who assist them through the process. This method is generally considered safe because it focuses on improving communication and decision-making rather than administering medications or performing invasive procedures.

Overall, the TELESCOPE program has shown promise in helping patients feel more supported and informed about their lung cancer screening choices without significant safety concerns. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the TELESCOPE intervention for lung cancer because it offers a more comprehensive approach than current standard care options. Unlike typical treatments that might focus solely on medication or surgery, TELESCOPE integrates smoking cessation support and low-dose CT screening for early detection, all guided by Nurse Navigators. This holistic method not only aims to address the cancer itself but also tackles smoking, a major risk factor, and ensures patients receive timely screening and diagnostic support, which could lead to earlier and more effective interventions.

What evidence suggests that the TELESCOPE intervention is effective for lung cancer screening?

Research shows that the TELESCOPE program, available to participants in this trial, uses telehealth to assist with decisions about lung cancer screening. Patient navigators lead this program, guiding individuals through the process of deciding whether to undergo screening. Studies have found that early detection of lung cancer with a low-dose CT scan can significantly reduce the risk of dying from the disease. By focusing on personalized screening based on individual risk, TELESCOPE aims to enhance the effectiveness of lung cancer screening. This approach helps individuals better understand their options and make informed choices about screening. ^{1 2 4 6 7}

Who Is on the Research Team?

Evelyn Arana, DrPH

Principal Investigator

Rutgers Cancer Institute of NJ

Are You a Good Fit for This Trial?

This trial is for Hispanic individuals at high risk for lung cancer. Participants should be comfortable with remote communication and willing to follow up after one week. Specific inclusion and exclusion criteria are not listed, but typically these would involve factors like age, health status, and risk factors for lung cancer.

Inclusion Criteria

Fluent in English

Aim 1 (Cultural Adaptation):

Identify as Hispanic and/or Latino(a)

Exclusion Criteria

Online surveys (N=130): Providers/administrators will be excluded if they are unable to provide informed consent, women who are pregnant

I speak English, am Hispanic or Latino(a), have no lung cancer history, haven't been screened for lung cancer in the last year, am considered a good candidate for curative treatment by my doctor, and can give informed consent.

I can provide informed consent.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Culturally adapted TELESCOPE intervention delivered by bilingual patient navigators, including support for smoking cessation and LDCT screening

1 week

1 visit (in-person or virtual)

Follow-up

Participants are monitored for feasibility, acceptability, and intervention impact, including follow-up assessments and LDCT completion

3 months

1 visit (in-person or virtual) at 1 week, medical record review at 3 months

Long-term Follow-up

Assessment of intervention feasibility and acceptability by clinicians, and monitoring of tobacco treatment referral and receipt

12 months

What Are the Treatments Tested in This Trial?

Interventions

• TELESCOPE

Trial Overview The TELESCOPE intervention involves culturally adapted decision coaching delivered remotely by bilingual patient navigators to help Hispanics decide about lung cancer screening. The study will compare this approach against standard care to see if it improves the uptake of low-dose CT scans and the quality of shared decision-making.

How Is the Trial Designed?

Group I: TELESCOPE intervention Experimental Treatment 1 Intervention

Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. If a participant is a current smoker then they are offered and navigated to evidence-based smoking cessation. If the participant is interested in screening, an LDCT is ordered. Support for screening, diagnostic testing and oncology care will be provided as needed from the Nurse Navigators.

Group II: Enhanced Usual Care Active Control 1 Intervention

Participants will be surveyed at baseline and at one-week after the scheduled primary care office visit. Primary and secondary outcome data related to the office visit will be collected.

Who Is Running the Clinical Trial?

Rutgers, The State University of New Jersey

Lead Sponsor

Trials

471

Recruited

81,700+

New Jersey Commission on Cancer Research

Collaborator

Trials

1

Recruited

100+

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11490179/

The TELEhealth Shared decision-making COaching and ... The trial's aims are to: (1) test the effectiveness of a decision coaching and navigation intervention for LCS delivered by patient navigators (TELESCOPE) ...

2. physiciansweekly.com physiciansweekly.com/post/telescope-intervention-to-improve-sdm-for-lung-cancer-screening-in-primary-care

TELESCOPE Intervention to Improve SDM for Lung Cancer ... Amivantamab–lazertinib significantly improved overall survival compared with osimertinib in EGFR-mutated advanced NSCLC. ... Test your ...

3. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/38746205/

a study protocol for delivering shared decision-making for lung ... This protocol describes a telehealth decision coaching intervention for LCS in primary care clinics delivered by patient navigators.

4. cinj.org cinj.org/3-5-million-nih-grant-rutgers-cancer-institute-new-jersey-will-support-new-lens-lung-cancer

$3.5 Million NIH Grant to Rutgers Cancer Institute will ... Early detection of lung cancer through low-dose CT scans has proven to be an effective way to reduce mortality and improve outcomes, however, ...

5. researchgate.net researchgate.net/publication/385048098_The_TELEhealth_Shared_decision-making_COaching_and_navigation_in_Primary_carE_TELESCOPE_intervention_a_study_protocol_for_delivering_shared_decision-making_for_lung_cancer_screening_by_patient_navigat

(PDF) The TELEhealth Shared decision-making COaching ... Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS's effectiveness. We assess current LCS practices ...

6. withpower.com withpower.com/trial/phase-respiratory-tract-neoplasms-8-2026-717b7

TELESCOPE for Lung Cancer · Info for Participants Hypothesis 2: The investigators expect that an adapted TELESCOPE intervention will result in higher uptake of LDCT and higher SDM quality for lung cancer ...

7. axisimagingnews.com axisimagingnews.com/imaging-insights/imaging-research/3-5m-nih-grant-to-support-telescope-a-new-lens-in-lung-cancer-screening

Grant to Support TELESCOPE Lung Cancer Screen Early detection of lung cancer through low-dose CT scans has proven to be an effective way to reduce mortality and improve outcomes, however, ...